Pfizer Inc. (TSX:PFE)
Canada · Delayed Price · Currency is CAD 12.23
+0.04 (0.33%)
Oct 6, 2026, 3:59 PM EST
Pfizer Revenue
Pfizer had revenue of $15.03B USD in the quarter ending June 28, 2026, with 2.60% growth. This brings the company's revenue in the last twelve months to $63.70B, down -0.21% year-over-year. In the year 2025, Pfizer had annual revenue of $62.58B, down -1.65%.
Revenue (ttm)
$63.70B
Revenue Growth
-0.21%
P/S Ratio
2.47
Revenue / Employee
$849.28K
Employees
75,000
Market Cap
222.89B CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.58B | -1.05B | -1.65% |
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | 15.90B | 32.26% |
| Dec 31, 2009 | 49.27B | 973.00M | 2.01% |
| Dec 31, 2008 | 48.30B | -122.00M | -0.25% |
| Dec 31, 2007 | 48.42B | 47.00M | 0.10% |
| Dec 31, 2006 | 48.37B | 966.00M | 2.04% |
| Dec 31, 2005 | 47.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.20B |
| Extendicare | 1.98B |
| Curaleaf Holdings | 1.87B |
| Green Thumb Industries | 1.72B |
| WELL Health Technologies | 1.52B |
| Sienna Senior Living | 1.08B |
| Knight Therapeutics | 547.31M |
| DRI Healthcare Trust | 285.04M |
Pfizer News
- 6 hours ago - Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026 - PRNewsWire
- 13 hours ago - Pfizer price target raised to $33 from $30 at Scotiabank - TheFly
- 16 hours ago - Pfizer Declares Fourth-Quarter 2026 Dividend - Business Wire
- 4 days ago - Pfizer says LITFULO significantly improved repigmentation in patients - TheFly
- 4 days ago - Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo - Business Wire
- 5 days ago - Trump Medicare drug pricing model may apply to only four companies after exemptions - Reuters
- 5 days ago - Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims - Reuters
- 5 days ago - Florida sues Pfizer over COVID vaccine marketing - TheFly